These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21571)

  • 1. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
    Mielke DH; Gallant DM; Kessler C
    Am J Psychiatry; 1977 Dec; 134(12):1371-5. PubMed ID: 21571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulpiride: evaluation of antipsychotic activity in schizophrenic patients.
    Mielke DH; Gallant DM; Roniger JJ; Kessler C; Kessler LR
    Dis Nerv Syst; 1977 Jul; 38(7):569-71. PubMed ID: 326504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
    Jeste DV; Neckers LM; Wagner RL; Wise CD; Staub RA; Rogol A; Potkin SG; Bridge TP; Wyatt RJ
    J Clin Psychiatry; 1981 Feb; 42(2):75-7. PubMed ID: 6109719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulpiride-induced tardive dystonia.
    Miller LG; Jankovic J
    Mov Disord; 1990; 5(1):83-4. PubMed ID: 1967484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
    Alfredsson G; Bjerkenstedt L; Edman G; Härnryd C; Oxenstierna G; Sedvall G; Wiesel FA
    Acta Psychiatr Scand Suppl; 1984; 311():49-74. PubMed ID: 6199949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical and pharmacodynamic evaluation of sulpiride.
    Rao VA; Bailey J; Bishop M; Coppen A
    Psychopharmacology (Berl); 1981; 73(1):77-80. PubMed ID: 6785794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties.
    Caley CF; Weber SS
    Ann Pharmacother; 1995 Feb; 29(2):152-60. PubMed ID: 7756714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulpiride--an antipsychotic agent: comparative trial vs. haloperidol.
    Cassano GB; Castrogiovanni P; Conti L; Bonollo L
    Psychopharmacol Bull; 1977 Jul; 13(3):41-3. PubMed ID: 18759
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride-induced tardive dyskinesia in childhood onset schizophrenia.
    Goyal N; Sinha VK
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):728-9. PubMed ID: 20347912
    [No Abstract]   [Full Text] [Related]  

  • 15. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride].
    Liu KL; Lung FW
    Kaohsiung J Med Sci; 1996 Dec; 12(12):685-90. PubMed ID: 9011126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-benefit assessment of sulpiride in the treatment of schizophrenia.
    Mauri MC; Bravin S; Bitetto A; Rudelli R; Invernizzi G
    Drug Saf; 1996 May; 14(5):288-98. PubMed ID: 8800626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dystonia associated with low-dose of amisulpride: a case report.
    Sevincok L; Balci V; Akyildiz U
    J Clin Psychopharmacol; 2008 Oct; 28(5):573-4. PubMed ID: 18794659
    [No Abstract]   [Full Text] [Related]  

  • 18. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zuclopenthixol dihydrochloride for schizophrenia.
    Kumar A; Strech D
    Schizophr Bull; 2009 Sep; 35(5):855-6. PubMed ID: 19661197
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms.
    Naber D; Finkbeiner C; Fischer B; Zander KJ; Ackenheil M
    Neuropsychobiology; 1980; 6(4):181-9. PubMed ID: 6104798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.